Profile data is unavailable for this security.
About the company
Xbrane Biopharma AB, formerly Xbrane Bioscience AB, is a Sweden-based provider of biotechnology research and development services. It develops biogenerics for injectable slow release drugs and high-yield protein expression technology for the development of biosimilars. The Company's main products are Sperotide, a generic on the originator drug marketed under the trademarks Decapeptyl, Trelstar and Pamorelin, as well as Xlucane, a biosimilar on the originator drug sold under the trademark Lucentis.
- Revenue in SEK (TTM)190.97m
- Net income in SEK-361.27m
- Incorporated2008
- Employees75.00
- LocationXbrane Biopharma ABRetzius Vag 8SOLNA 171 65SwedenSWE
- Phone+46 855905600
- Websitehttps://xbrane.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intervacc AB | 8.93m | -102.77m | 296.13m | 15.00 | -- | 1.34 | -- | 33.18 | -1.40 | -1.40 | 0.1221 | 2.91 | 0.0365 | 3.25 | 1.55 | 595,066.70 | -41.96 | -17.62 | -45.32 | -18.77 | -589.11 | -243.59 | -1,151.30 | -626.90 | 4.33 | -- | 0.0006 | -- | -17.23 | -25.79 | -60.31 | -- | -38.72 | -- |
| Ultimovacs ASA | 0.00 | -178.42m | 310.60m | 25.00 | -- | 1.19 | -- | -- | -5.17 | -5.17 | 0.00 | 7.53 | 0.00 | -- | -- | 0.00 | -44.31 | -28.80 | -50.09 | -31.12 | -- | -- | -- | -- | -- | -- | 0.0136 | -- | -- | -- | -12.78 | -- | -45.35 | -- |
| Lytix Biopharma AS | 4.00m | -88.16m | 318.47m | 10.00 | -- | 5.07 | -- | 79.56 | -2.16 | -2.16 | 0.0981 | 1.26 | 0.0368 | -- | 0.4091 | 399,100.00 | -80.96 | -56.91 | -94.07 | -65.83 | -- | -- | -2,202.36 | -771.78 | -- | -- | 0.0095 | -- | -63.82 | 63.94 | -56.77 | -- | -- | -- |
| Ascelia Pharma AB | 0.00 | -88.76m | 355.13m | 13.00 | -- | 5.83 | -- | -- | -2.63 | -2.63 | 0.00 | 1.80 | 0.00 | -- | -- | 0.00 | -65.17 | -- | -78.39 | -- | -- | -- | -- | -- | -- | -- | 0.2302 | -- | -- | -- | 16.72 | -- | -- | -- |
| Medivir AB | 7.73m | -96.52m | 361.93m | 10.00 | -- | 1.71 | -- | 46.80 | -1.46 | -1.46 | 0.1028 | 1.89 | 0.032 | -- | 1.56 | 773,300.00 | -40.00 | -28.91 | -47.20 | -34.77 | -888.81 | -467.42 | -1,248.18 | -675.96 | -- | -- | 0.0482 | -- | 73.16 | -20.39 | -0.6275 | -- | -47.96 | -- |
| Magle Chemoswed Holding AB | 170.01m | 12.23m | 365.04m | 78.00 | 29.85 | 2.26 | 14.57 | 2.15 | 1.13 | 1.13 | 15.74 | 14.95 | 0.6068 | 0.493 | 8.30 | 2,179,628.00 | 4.36 | 2.52 | 5.86 | 3.52 | 90.58 | 85.67 | 7.19 | 3.92 | 0.6356 | 6.35 | 0.3081 | -- | 17.00 | 9.97 | 33.07 | -- | -6.34 | -- |
| INIFY Laboratories AB | 3.42m | -51.36m | 381.11m | 23.00 | -- | 5.22 | -- | 111.54 | -1.13 | -1.13 | 0.0753 | 1.61 | 0.032 | 2.99 | 0.6608 | -- | -48.10 | -- | -48.10 | -- | 76.42 | -- | -1,503.10 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- |
| Lifecare ASA | 13.13m | -35.37m | 406.49m | 32.00 | -- | 5.02 | -- | 30.97 | -0.2454 | -0.2454 | 0.092 | 0.4163 | 0.1621 | -- | 4.90 | 408,943.10 | -43.60 | -40.00 | -49.97 | -45.26 | -- | -- | -269.03 | -175.53 | -- | -- | 0.1812 | -- | -40.88 | 30.29 | -101.74 | -- | -- | -- |
| Herantis Pharma Oyj | 0.00 | 3.19m | 426.90m | 10.00 | 147.57 | 7.91 | 133.64 | -- | 0.0126 | 0.0126 | 0.00 | 0.2344 | 0.00 | -- | -- | 0.00 | 4.31 | -80.46 | 6.16 | -104.37 | -- | -- | -- | -- | -- | -- | 0.0073 | -- | -- | -- | 103.00 | -- | -- | -- |
| Xbrane Biopharma AB | 190.97m | -361.27m | 455.79m | 75.00 | -- | 1.16 | -- | 2.39 | -1.33 | -1.58 | 0.6978 | 0.2577 | 0.2465 | 1.34 | 332.12 | 2,053,430.00 | -46.63 | -40.98 | -78.01 | -67.24 | 15.43 | -- | -189.18 | -364.40 | 1.43 | -31.13 | 0.3693 | -- | 314.33 | 63.42 | -91.10 | -- | 60.02 | -- |
| Mendus AB (publ) | 0.00 | -107.07m | 510.65m | 28.00 | -- | 0.6511 | -- | -- | -0.1573 | -0.1573 | 0.00 | 0.7787 | 0.00 | -- | -- | 0.00 | -16.09 | -18.84 | -17.35 | -20.21 | -- | -- | -- | -28,474.53 | -- | -- | 0.0348 | -- | -100.00 | -- | 26.78 | -- | -- | -- |
| Initiator Pharma A/S | 0.00 | -34.51m | 539.64m | 3.00 | -- | 15.77 | -- | -- | -0.6338 | -0.6338 | 0.00 | 0.6468 | 0.00 | -- | -- | 0.00 | -70.60 | -68.27 | -73.77 | -74.02 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 27.95 | -- | -- | -- |
| Enzymatica AB (publ) | 47.29m | -53.67m | 547.89m | 18.00 | -- | 6.53 | -- | 11.59 | -0.3247 | -0.3247 | 0.2866 | 0.4841 | 0.3269 | 1.38 | 6.48 | -- | -37.11 | -27.36 | -39.16 | -33.98 | 64.25 | 65.08 | -113.50 | -66.12 | -- | -23.26 | 0.2502 | -- | 4.00 | -0.6382 | 27.57 | -- | 7.02 | -- |
| Bergenbio ASA | 522.58k | -154.99m | 555.55m | 16.00 | -- | 408.26 | -- | 1,063.08 | -0.1849 | -0.1849 | 0.0003 | 0.0347 | 0.0047 | -- | 0.0485 | 20,840.00 | -139.81 | -66.15 | -275.19 | -78.74 | -- | -- | -29,658.54 | -11,419.44 | -- | -- | 0.00 | -- | -9.00 | -31.43 | 36.98 | -- | -- | -- |
| Promimic AB | 39.53m | -9.38m | 602.63m | 17.00 | -- | 8.26 | -- | 15.24 | -0.5067 | -0.5067 | 2.14 | 3.91 | 0.4533 | -4.61 | 5.46 | 2,325,471.00 | -10.75 | -24.89 | -12.43 | -29.25 | 104.25 | 101.23 | -23.73 | -89.47 | 4.13 | -- | 0.00 | -- | 128.63 | -- | 41.95 | -- | -- | -- |
Data as of May 31 2024. Currency figures normalised to Xbrane Biopharma AB's reporting currency: Swedish Krona SEK
4.64%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Handelsbanken Fonder ABas of 30 Apr 2024 | 36.55m | 2.40% |
| Swedbank Robur Fonder ABas of 31 Aug 2023 | 13.01m | 0.86% |
| Teknik Innovation Norden Fonder ABas of 31 Aug 2023 | 11.57m | 0.76% |
| SEB Investment Management ABas of 30 Apr 2024 | 7.60m | 0.50% |
| Skandia Investment Management ABas of 28 Mar 2024 | 1.13m | 0.07% |
| Storebrand Asset Management ASas of 31 Jan 2024 | 316.72k | 0.02% |
| SSgA Funds Management, Inc.as of 09 May 2024 | 101.74k | 0.01% |
| WBS H�nicke Verm�gensverwaltung GmbHas of 31 Mar 2024 | 85.00k | 0.01% |
| Danske Bank A/S (Investment Management)as of 30 Apr 2024 | 66.66k | 0.00% |
| Case Kapitalf�rvaltning ABas of 30 Nov 2022 | 23.05k | 0.00% |
More ▼
Data from 31 Dec 2022 - 30 Apr 2024Source: FactSet Research Systems Inc.
